268 related articles for article (PubMed ID: 31101066)
1. The promise of Immuno-oncology: implications for defining the value of cancer treatment.
Kaufman HL; Atkins MB; Subedi P; Wu J; Chambers J; Joseph Mattingly T; Campbell JD; Allen J; Ferris AE; Schilsky RL; Danielson D; Lichtenfeld JL; House L; Selig WKD
J Immunother Cancer; 2019 May; 7(1):129. PubMed ID: 31101066
[TBL] [Abstract][Full Text] [Related]
2. Customer pyramid framework for CAR T-cell therapies in immuno-oncology.
Malik NN; Durdy MB
Drug Discov Today; 2016 Oct; 21(10):1563-1565. PubMed ID: 27640934
[No Abstract] [Full Text] [Related]
3. Advanced APMs and the emerging role of immuno-oncology agents: balancing innovation and value.
Seiden MV; Neubauer M; Verrilli D
Am J Manag Care; 2017 Feb; 23(2 Spec No.):SP69-SP77. PubMed ID: 28298130
[No Abstract] [Full Text] [Related]
4. Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.
Carroll R; Bortolini M; Calleja A; Munro R; Kong S; Daumont MJ; Penrod JR; Lakhdari K; Lacoin L; Cheung WY
BMC Cancer; 2022 Mar; 22(1):255. PubMed ID: 35264135
[TBL] [Abstract][Full Text] [Related]
5. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Clinical development of immuno-oncology in China.
Wu DW; Huang HY; Tang Y; Zhao Y; Yang ZM; Wang J; Wang SH; Yu Y; Fang Y; Fang H; Bai Y; Sun C; Fan Q; Yu AQ; Wang HL; Du CX; Chen K; Huang MD; Zhang Y; Li N; Xu BH; Sun Y; He J
Lancet Oncol; 2020 Aug; 21(8):1013-1016. PubMed ID: 32758460
[No Abstract] [Full Text] [Related]
8. The hubris and humility of cancer pharmacology in the post immuno-oncology era.
Lazo JS
Pharmacol Res Perspect; 2019 Dec; 7(6):e00527. PubMed ID: 31624635
[TBL] [Abstract][Full Text] [Related]
9. Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.
Anagnostou V; Yarchoan M; Hansen AR; Wang H; Verde F; Sharon E; Collyar D; Chow LQM; Forde PM
Clin Cancer Res; 2017 Sep; 23(17):4959-4969. PubMed ID: 28864724
[TBL] [Abstract][Full Text] [Related]
10. Master protocols in immuno-oncology: do novel drugs deserve novel designs?
Mazzarella L; Morganti S; Marra A; Trapani D; Tini G; Pelicci P; Curigliano G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32238471
[TBL] [Abstract][Full Text] [Related]
11. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project.
Herbrand AK; Schmitt AM; Briel M; Diem S; Ewald H; Hoogkamer A; Joerger M; Mc Cord KA; Novak U; Sricharoenchai S; Hemkens LG; Kasenda B
ESMO Open; 2019; 4(6):e000596. PubMed ID: 31803503
[TBL] [Abstract][Full Text] [Related]
12. Cancer Nanomedicine: Lessons for Immuno-Oncology.
Sengupta S
Trends Cancer; 2017 Aug; 3(8):551-560. PubMed ID: 28780932
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality-of-life assessment of patients with solid tumors on immuno-oncology therapies.
Voon PJ; Cella D; Hansen AR
Cancer; 2021 May; 127(9):1360-1368. PubMed ID: 33662145
[TBL] [Abstract][Full Text] [Related]
14. [The revolution of immuno-oncology therapy: specificities for the physicians].
Dubois M; Ardin C; André F; Scherpereel A; Mortier L
Med Sci (Paris); 2019 Dec; 35(12):946-948. PubMed ID: 31903898
[TBL] [Abstract][Full Text] [Related]
15. End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.
Hoering A; Durie B; Wang H; Crowley J
Future Oncol; 2017 Jun; 13(13):1181-1193. PubMed ID: 28395525
[TBL] [Abstract][Full Text] [Related]
16. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).
Golan T; Milella M; Ackerstein A; Berger R
J Exp Clin Cancer Res; 2017 Dec; 36(1):192. PubMed ID: 29282151
[TBL] [Abstract][Full Text] [Related]
17. Trends and challenges in immuno-oncology trials.
Kiernan B
Drugs Today (Barc); 2016 Jul; 52(7):387-93. PubMed ID: 27540597
[TBL] [Abstract][Full Text] [Related]
18. The emerging role of epigenetic therapeutics in immuno-oncology.
Topper MJ; Vaz M; Marrone KA; Brahmer JR; Baylin SB
Nat Rev Clin Oncol; 2020 Feb; 17(2):75-90. PubMed ID: 31548600
[TBL] [Abstract][Full Text] [Related]
19. Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs.
Huntington SF; Davidoff AJ; Gross CP
J Clin Oncol; 2020 Feb; 38(4):351-358. PubMed ID: 31804866
[No Abstract] [Full Text] [Related]
20. Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.
Maio M; Coukos G; Ferrone S; Fox BA; Fridman WH; Garcia PL; Lahn M; Provendier O; Russo V; Rüttinger D; Shalabi A; Trajanoski Z; Viallet J; Wolchok JD; Ibrahim R
Cancer Immunol Immunother; 2019 Jan; 68(1):1-9. PubMed ID: 30564889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
